Latest news

• Celgene joins PD-1 race via partnership with BeiGene

  BeiGene is also acquiring Celgene's commercial operations in Asia with the right to sell blood cancer therapies Revlimid (lenalidomide) and Vidaza (azacitidine) and Abraxane (albumin-bound paclitaxel) for pancreatic cancer -

• Celgene bags US priority review for cancer metabolism drug

  For Celgene, enasidenib will slot into its haematological malignancy portfolio alongside Vidaza (azacitidine), a drug used first-line to treat AML patients who cannot receive a stem cell transplant and which

• AZ, BMS and Boehringer among UK Prix Galien finalists

  Pompe Disease. azacitidine. Vidaza. Celgene. Myslodysplastic Syndrome. omalizumab. Xolair. Novartis. Sever persistent allergic asthma.

• NICE rejects Celgene's Vidaza for leukaemia

  The rejection is for the use of Vidaza (azacitidine) as a treatment for newly-diagnosed AML in patients aged 65 or over who are not eligible for haematopoietic stem cell transplantation ... According to NICE, the incremental cost-effectiveness ratio (ICER

• Novartis claims FDA breakthrough status for leukaemia treatment

  Should it reach the market PKC412 will compete with the likes of Celgene's Vidaza (azacitidine), which was first approved in 2008 and last November won an expanded indication to treat